Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07229261 · ClinicalTrials.gov registry record · NA
MitoQ to Improve Vascular Funciton in Preeclampsia
A NA study, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT07229261 is a NA study that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 80 participants.
The verdict
NCT07229261, a NA study, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Mitoquinol Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-03-18 |
| Est. Completion | 2027-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07229261
The ClinicalTrials.gov registry entry for NCT07229261 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07229261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07229261 about?
NCT07229261 is a clinical study titled "MitoQ to Improve Vascular Funciton in Preeclampsia". Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evalu...
What is the current status of trial NCT07229261?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2026-03-18. Estimated completion is 2027-09-30.
What interventions are being tested in trial NCT07229261?
The interventions under investigation include: Placebo (OTHER), Mitoquinol Mesylate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07229261?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.